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Abstract
Colorectal cancer (CRC) was the third-leading cause of cancer death in 
Taiwan in 2008. The natural history of CRC provides a chance for screen-
ing and prevention. Most CRC develops from adenomatous polyps. This 
progression takes at least 10 years in most people. About 90% of CRC 
develops after 50 years of age. Screening tests can identify cancers, usu-
ally at an early stage, and polyps, which can be removed before malignant 
change. Removal of adenomatous polyps can reduce the risk of developing 
CRC by up to 90%. Several factors increase the risk of CRC: a familial his-
tory of colon adenomas, CRC, familial adenomatous polyposis, or hereditary 
nonpolyposis colon cancer; a personal history of treated CRC or adenoma, 
or ulcerative pancolitis for more than 10 years; old age; a diet high in fat 
and red meat and low in fiber; a sedentary lifestyle; and cigarette smoking. 
Colonoscopy is the best screening method, and detects most small polyps 
and almost all large polyps and cancers. Polyps can be removed during 
colonoscopy. The risk of serious bleeding or perforation is about 1/1000. 
In the future, computed tomography colonography may become a good 
screening tool. The double contrast barium enema has largely been replaced 
by other screening methods. Combined screening with a fecal occult blood 
test and sigmoidoscopy is a possible option. People with an average risk of 
CRC should begin screening at 50 years of age. Colonoscopy is recommended 
every 10 years or computed tomography colonography, sigmoidoscopy, 
or a double contrast barium enema every 5 years. Stool testing once per 
year is another alternative. Patients with an elevated risk should be screened 
with colonoscopy, usually beginning at 40 years of age. Screening for fam-
ily members of those with familial adenomatous polyposis and hereditary 
nonpolyposis colon cancer should be more intense and be initiated at 20 
years of age. If polyps are found and removed during a screening colonos-
copy, a surveillance colonoscopy should be done 1–5 years later, accord-
ing to the size and histology of the removed adenoma. [Tzu Chi Med J 
2009;21(3):190–196]
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1. Introduction
Colorectal cancer (CRC) is the third most prevalent 
form of cancer and the second leading cause of can-
cer death in the United States [1,2]. It accounts for 
up to 9% of cancer deaths overall. Up to one third of 
people with CRC will ultimately die of it. The lifetime 
incidence of CRC for an average-risk person is about 
5%. The incidence rate of CRC in the United States 
has been declining, partly because of screening. The 
screening rate for CRC in adults over 50 years of age 
has increased recently. The rate was 60.8% in 2006, 
but this is not thought to be satisfactory [3–5]. In con-
trast, the incidence rate of CRC in Taiwan is rising, 
probably because of behavior changes and the differ-
ent screening policy [6]. It was the third leading cause 
of cancer death in Taiwan in 2008 (Fig. 1). The lifestyle 
in Taiwan has become more and more westernized in 
the past few decades. The practice of screening fecal 
occult blood tests for people over 50 years old started 
only several years ago.
Prevention of CRC is feasible, as demonstrated by 
several facts. First, CRC is rare before the age of 40 
years; around 90% of cases occur after the age of 50 
years [1]. The incidence rate rises with increasing age, 
and reaches 3.7/1000/year by the age of 80 years [1]. 
Second, most cases of CRC develop from an adenoma. 
A sequence of small adenoma to large adenoma to 
dysplasia and then to cancer is suggested [7]. Third, 
the development of adenoma from normal mucosa 
may take more than 10 years, and the development 
of cancer from adenoma may take 2–30 years [8]. 
Because of the slow progression rate from normal 
mucosa to adenoma, and to cancer, CRC can be pre-
vented if adenomas are found and removed before 
malignant transformation (Fig. 2). The National Polyp 
Study Work Group reported that in a group of 1418 
patients whose adenomas were removed and were 
followed for an average of 6 years, the incidence of 
CRC decreased by 88–90% compared with that in 
patients whose adenomas were not removed, and by 
76% compared with that in the general population 
[9].
2. Screening recommendations 
according to risk level
Fig. 3 shows an algorithm for the screening policy 
recommended by the American Cancer Society and 
the United States Multi-Society Task Force on Colorectal 
Cancer, which was updated in 2008 [10]. Patients with 
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Fig. 1 — Leading causes of cancer death in Taiwan 2008. 
Data taken from Reference 6.
A B C
Fig. 2 — (A) Pedunculated polyp in the sigmoid colon of a patient seen on screening colonoscopy performed in our 
hospital. (B) The polyp was grasped by a snare. (C) It was then cut off with an electric current.
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symptoms suspected to indicate CRC are advised to 
undergo a diagnostic work-up without delay. For asymp-
tomatic patients, the screening policy depends on 
specific age and risk level.
The risk level should be determined by the personal 
and familial history of CRC and adenomas, starting at 
the age of 20 years, with reassessment every 5 years. 
The risk level is high for patients who have been treated 
for CRC previously, up to a three-fold increased risk 
of CRC compared with the general population [11]. 
Patients who had colorectal adenomas removed pre-
viously also have an increased risk of CRC [12]. They 
should be followed with colonoscopy (the nature 
of follow-up depends on the nature of the removed 
adenomas, as will be discussed later). Patients with 
ulcerative pancolitis for more than 8–10 years should 
be surveyed with colonoscopy every year with segmen-
tal random biopsies.
Family members of patients with familial adeno-
matous polyposis syndrome have hundreds to thou-
sands of polyps throughout the colon beginning in 
adolescence [13]. All family members should have 
genetic counseling and genetic testing when available. 
A screening sigmoidoscopy or colonoscopy should 
be conducted before the age of 20 years. Total colon 
colectomy is advised if the patient is confirmed to har-
bor the adenomatous polyposis coli gene, because 
CRC will develop in nearly 100% of these cases before 
Symptoms suggestive of colorectal cancer?
No Yes
Risks?
Average
Age?
< 50 yr ≥ 50 yr
Increased
Personal history?
Do not
screen
Colonoscopy
every 10 yr
Colorectal cancer,
adenoma, or
ulcerative colitis
Genetic
syndromes:
FAP, HNPCC
Family history?
Diagnostic studies
History?
If positive
Colonoscopy
Survey
colonoscopy
Average screening
starts at 40 yr
Genetic testing
and counseling,
early screening
CRC or adenoma in
1 FDR < 60 yr, or
≥ 2 FDR any age
CRC or adenoma
in FDR ≥ 60 yr or
CRC in ≥ 2 SDR
Colonoscopy begins at
40 yr or 10 yr earlier
then age of youngest
relative at diagnosis
– CTC every 5 yr
– Sigmoidoscopy every 5 yr
– DCBE every 5 yr
– gFOBT every yr
– FIT every yr
– sDNA every yr
or
Fig. 3 — Algorithm of the guidelines recommended by the American Cancer Society and the United States Multi-Society 
Task Force on Colorectal Cancer. CTC = computed tomography colonography; DCBE = double-contrast barium enema; 
gFOBT = guaiac-based fecal occult blood test; FIT = fecal immunological test; sDNA = stool DNA panel test; FAP = familial 
adenomatous polyposis syndrome; HNPCC = hereditary nonpolyposis colon cancer syndrome; CRC = colorectal cancer; 
FDR = first-degree relatives; SDR = second-degree relatives. Modified from Reference 10.
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the age of 50 years. Hereditary nonpolyposis colon 
cancer is a syndrome characterized by proximal colon 
cancers (and other cancers including endometrium, 
stomach, ovary, pancreas, ureter and kidney, biliary 
tract, and brain) in relatively young members of a fam-
ily [14]. It should be suspected if more than one family 
member had hereditary nonpolyposis colon cancer-
related cancer at a young age (between 30 and 40 
years of age). Genetic counseling and testing for DNA 
mismatch repair genes are suggested. Colonoscopy 
screening should be started at the age of 30 or 40 
years.
The risk of CRC is increased in family members 
of patients with CRC or colorectal adenoma [15–17]. 
Persons with one first-degree relative who had CRC 
diagnosed before the age of 60 years, or two or more 
first-degree relatives who had CRC or adenoma at any 
age, should have a colonoscopy screening starting at 
the age of 40 years, or 10 years earlier than the age 
at diagnosis of the youngest index case—whichever 
is earlier. Persons with one first-degree relative who 
had CRC or adenoma diagnosed after the age of 60 
years, or two or more second-degree relatives with 
CRC, should have screening tests on the same sched-
ule as average-risk persons, but starting at the age of 
40 years.
Several risk factors for CRC have been suggested by 
observational studies (Table 1) [18], but they do not 
require changes in screening recommendations.
3. Screening methods
Besides colonoscopy, several methods have been 
recommended for CRC screening. These include the 
guaiac-based fecal occult blood test, immunological 
fecal occult blood test, stool DNA test, flexible sig-
moidoscopy, double-contrast barium enema (DCBE), 
and computed tomography (CT) colonography. Factors 
to be considered in the choice of a screening test are 
listed in Table 2 [8]. No single test is superior to the 
others. Patient preference should also be considered. 
An annual immunological fecal occult blood test (iFOBT) 
for people aged 50 years or more, and a colonoscopy 
if the iFOBT is positive, is the current screening policy 
for CRC recommended by the Department of Health 
in Taiwan.
The guaiac-based fecal occult blood test (gFOBT) 
is based on a peroxidase reaction by heme, which 
transforms guaiac into a blue color. It can be affected 
by certain components of food. Patients should eat a 
high fiber diet for 2 days with no red meat, vitamin C, 
or gastric irritant drugs. Three stool samples should 
be obtained. It has been shown that biennial gFOBT 
tests can reduce CRC mortality by up to 30% after 
13 years [19]. Slightly lower mortality reductions (13–
18%) have been reported in other trials [20–23]. 
Theoretically, FOBT cannot detect most adenomas, 
because adenomas seldom bleed unless they are 
large. The test results in many false positives, lead-
ing to many unnecessary colonoscopies. The need 
for a restricted diet for gFOBT decreases screening 
compliance. An annual gFOBT remains one of the 
recommended screening methods for CRC, but it is 
gradually being replaced by iFOBT.
iFOBT is based on immunological detection of 
human (hemo-) globin in stool, and does not detect 
upper gastrointestinal bleeding (globin is digested) or 
food peroxidase (including animal globin). It requires 
only one stool sample and no diet restriction. It is 
more expensive than gFOBT. The sensitivity and specifi-
city for CRC and adenoma detection with iFOBT are 
higher than those of gFOBT [24–26]. The new quanti-
tative iFOBT [27] has shown even better perform-
ance, with a sensitivity and specificity of 94% and 87% 
Table 1 — Factors associated with an increased and 
decreased risk of colorectal cancer
Increased risk Decreased risk
Consumption of red meat Consumption of vegetables, fruits,
  and fiber
Lack of physical activity Multivitamins (with folic acid)
Obesity Postmenopausal hormone use
Cigarette smoking Calcium supplementation
Alcohol use Selenium
  Aspirin and other nonsteroidal 
 anti-inflammatory drugs
Modified from Reference 18.
Table 2 — Summary of the characteristics of screening tests for colorectal cancer and adenomas
 For cancer For polyps Complexity Effect Evidence Risk
gFOBT + + + + +++ −
iFOBT + + + ++ + −
Sigmoidoscopy ++ +++ ++ +++ ++ ++
DCBE ++ ++ +++ ++++ + ++
Colonoscopy ++++ +++++ ++++ +++++ + +++
CTC +++ ++++ +++ ++++ + +
sDNA ++ ++ ++ ++ + −
gFOBT = guaiac-based fecal occult blood test; iFOBT = immunological fecal occult blood test; DCBE = double-contrast barium enema; CTC = computed 
tomography colonography; sDNA = stool DNA panel test. Modified from Reference 8.
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for CRC and 67% and 91% for advanced adenoma, 
respectively. The quantitative iFOBT is used for mass 
screening of CRC in the general population by the 
Department of Health in Taiwan.
A panel of DNA markers in stool samples has been 
used to screen for CRC [28,29]. The sensitivity for 
detecting CRC ranged from 20% to 71%, with a spe-
cificity of around 82–96%. However, it misses many 
cancers and advanced adenomas detected by colon-
oscopy. The test is not cost effective at present.
Persons having a DCBE must undergo bowel prep-
aration to visualize the entire bowel and the test is 
relatively safe. It can detect most CRCs and about half 
of large (> 1 cm) polyps [30]. Any DCBE abnormalities 
must be confirmed by colonoscopy. It can miss up to 
20% of CRC [31]. False-positive findings due to stool 
or air are common. The radiation dose is also a con-
cern. The use of DCBE has been declining. The pro-
cedure might therefore be limited by insufficient 
training of technicians and radiologists. It may be of 
value where colonoscopy resources are limited.
Sigmoidoscopy refers to the use of a 60-cm flexible 
endoscope. Around two-thirds of CRC and adenoma 
occur in the distal 60 cm of the large bowel [32]. The 
patient needs minimal preparation and it can be done 
anytime in the office of a family doctor or an endo-
scopist. The procedure is considered inadequate if 
the scope cannot observe at least 40 cm in depth. 
The most serious complication of sigmoidoscopy is 
perforation, which occurs in around 0.88 per 1000 
procedures [33]. Case-control studies have shown 
that sigmoidoscopy reduces CRC mortality by up to 
one third [34–36]. A surveillance colonoscopy should 
follow a positive sigmoidoscopy.
Colonoscopy gives a direct view of the mucosa, and 
biopsy of cancer and removal of most adenomas can 
be completed during the same procedure. Removal of 
polyps can prevent CRC [9]. There are no randomized 
controlled studies showing that colonoscopy reduces 
CRC mortality in persons of average risk. The rate of 
perforation or major bleeding is about 1 in 1000 colon-
oscopies [33,37]. Colonoscopy requires vigorous bowel 
preparation, is rather uncomfortable for most patients, 
may require conscious sedation, and requires the pa-
tient to be accompanied after the procedure. The sen-
sitivity is operator-dependent. The detection rates for 
neoplasms are higher if the withdrawal-observation 
time is 6 minutes or longer [38]. In one study, the 
overall miss rate for polyps was 22%: 2% for adeno-
mas 10 mm or larger, and 25% for adenomas smaller 
than 5 mm [39].
CT colonography (formerly known as virtual colon-
oscopy) requires bowel preparation in a similar way 
to colonoscopy. The technique is gradually improving 
and with it the sensitivity and specificity for CRC and 
adenoma detection [40]. Colonoscopy is needed fol-
lowing a positive CT colonography finding. Radiation 
exposure is a concern. Extracolonic lesions may be 
found incidentally, which may cause undue anxiety. 
Sensitivity for large adenomas is good but flat or de-
pressed adenomas may easily be missed. As the pro-
cedure becomes more sophisticated, it may replace 
colonoscopy as a first-line screening tool [41].
Some colon cancers arise from nonpolypoid (flat 
or depressed) lesions which are difficult to identify 
even with colonoscopy; careful observation and 
often special stains are needed. Nonpolypoid adeno-
mas may be more likely to have dysplasia or cancer 
than polypoid ones of the same sizes [42–44]. These 
may account for up to one third of all adenomas and 
can only be detected by colonoscopy. For this rea-
son, colonoscopy remains the gold standard for CRC 
detection.
4. Surveillance colonoscopy
Once polyps are found, they should be completely 
removed. If severe dysplasia or carcinoma in situ is 
found, the resection margin should be free of any sus-
picious invasion. If there is doubt, colonoscopy should 
be repeated to see if any residual lesions remain, and 
these should be excised as completely as possible. 
If the malignant portion is poorly differentiated, there 
is vascular or lymphatic invasion, or the resection mar-
gin is not free, further evaluation with CT or positron 
emission tomography and surgical intervention should 
be considered.
After the complete removal of polyps, patients 
should be followed with surveillance colonoscopy. The 
interval of surveillance colonoscopy depends on the 
nature and number of polyps found. The histology of 
polyps can be roughly classified into either hyper-
plastic or adenomatous polyps. Although hyperplastic 
polyps have a characteristic appearance, biopsy is re-
quired for diagnosis. Hyperplastic polyps have a low 
risk of malignant change except in the unusual case 
of hyperplastic polyposis syndrome [45]. Around two 
thirds of polyps are adenomatous. Adenomas are 
found in up to 25% of persons aged 50 years, and in 
up to 50% of persons up to the age of 70 years [46]. 
The risk of CRC increases with the size, number, and 
aggressive histology (villous vs. tubular, and grade of 
dysplasia) of adenomas [47,48]. Larger adenomas are 
more likely to have a villous component and dysplasia. 
Lesions with a villous histology are more prone to 
malignant change. Higher grades of dysplasia reflect 
a higher likelihood of change and more rapid malig-
nant change. The recommended surveillance inter-
vals suggested by the US Multi-Society Task Force on 
Colorectal Cancer and the American Cancer Society 
[47] are summarized in Fig. 4.
The effectiveness of colonoscopy in preventing CRC 
depends on the detection and removal of adenomas. 
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This in turn depends on the adequacy of bowel prep-
aration and careful mucosal visualization. The term 
“interval cancer” refers to CRC found within 5 years 
of a completely negative colonoscopy. Interval can-
cer accounts for about 5% of registered CRCs [49,50]. 
Research has shown that endoscopists who had longer 
mean times for withdrawal of the colonoscope had 
greater rates of adenoma detection [51]. The endo-
scopist should look carefully behind folds, efface 
mucosa where feces or bubbles interfere with view-
ing, dedicate sufficient time, and avoid fatigue during 
examination.
5. Summary
CRC is both common and lethal. However, it is pre-
ventable, principally because of its slow development 
and transformation from adenoma to carcinoma, 
occurring mostly after the age of 50 years. Screening 
is recommended starting from the age of 50 years 
for people of average risk. People with increased risk 
should be screened earlier, as depicted in Fig. 3. There 
are several methods suggested for CRC screening. At 
present, the iFOBT is provided free by the Department 
of Health in Taiwan. Colonoscopy is the gold stan-
dard for CRC detection, provided that the procedure 
is performed adequately. Surveillance colonoscopy is 
recommended after the complete removal of adeno-
mas, as recommended in Fig. 4. However, it should 
be stressed that recommendations are for screening 
asymptomatic people. One should suggest colonos-
copy directly when a patient is symptomatic.
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